Opko Health OPK Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Gross Profit by Business | ||||||
| Diagnostics | $60.64M-24.1% | $62.92M-19.9% | $78.68M+13.8% | $76.27M+3.0% | $79.87M+15.6% | |
| Pharmaceutical | $148.44M+6.6% | $143.02M+2.2% | $147.89M+2.5% | $140.54M-21.4% | $139.2M-34.2% | |
| Operating Income by Business | ||||||
| Pharmaceutical | -$93.26M+0.7% | -$98.34M-13.3% | -$89.76M— | -$97.77M— | -$93.88M— | |
| Total Assets by Business | ||||||
| Diagnostics | $1.55B-26.5% | $1.68B-24.7% | $1.83B-22.9% | $1.97B-21.4% | $2.1B-17.7% | |
| Pharmaceutical | $5.3B— | —— | —— | —— | —— | |
| Selling General And Administrative Expense by Business | ||||||
| Diagnostics | $117.5M-40.5% | $129.3M-37.0% | $146.81M-30.7% | $186.25M-2.7% | $197.38M-0.1% | |
| Pharmaceutical | $55.36M-0.6% | $53.87M-7.1% | $52.71M-9.4% | $54.81M-3.8% | $55.68M-2.0% | |
| Research And Development Expense by Business | ||||||
| Diagnostics | $1.41M-27.5% | $1.64M-21.1% | $1.84M-15.2% | $2.05M-11.3% | $1.95M-23.5% | |
| Pharmaceutical | $120.42M+7.5% | $121.91M+18.3% | $119.51M+25.9% | $118.11M+33.5% | $112.01M+29.5% | |
| D&A by Business | ||||||
| Diagnostics | $17.6M-26.8% | $19.37M-26.1% | $21.26M-24.9% | $22.68M-25.8% | $24.05M-27.0% | |
| Pharmaceutical | $72.73M+1.3% | $72.26M+0.4% | $72.03M+0.3% | $72.03M+0.7% | $71.8M+0.5% | |
| Goodwill by Business | ||||||
| Diagnostics | $653.77M-20.3% | $653.77M-25.3% | $710.03M-24.3% | $766.3M-23.5% | $820.59M-23.1% | |
| Pharmaceutical | $1.28B— | —— | —— | —— | —— | |
| Cost of Goods Sold by Business | ||||||
| Diagnostics | $278.98M-26.0% | $307.35M-23.6% | $323.62M-26.0% | $352.06M-20.0% | $376.75M-15.2% | |
| Pharmaceutical | $93.07M-0.6% | $93.59M+1.2% | $91.88M-3.0% | $95.16M+0.2% | $93.59M-2.9% | |
| Amortization Of Intangible Assets by Business | ||||||
| Diagnostics | $11.09M-29.3% | $12.3M-27.3% | $13.74M-23.6% | $14.69M-23.1% | $15.67M-22.2% | |
| Pharmaceutical | $65.91M+0.8% | $65.59M-0.2% | $65.44M-0.6% | $65.39M-0.6% | $65.39M-0.7% | |
| Goodwill Foreign Currency Translation Gain Loss by Business | ||||||
| Diagnostics | $0— | $0— | $0— | $0— | $0— | |
| Goodwill Impaired Accumulated Impairment Loss by Business | ||||||
| Diagnostics | $71.91M0.0% | $71.91M0.0% | $71.91M0.0% | $71.91M0.0% | $71.91M0.0% | |
| Pharmaceutical | $46.79M— | —— | —— | —— | —— | |
| Revenue by Product | ||||||
| Rayaldee | $59.08M-12.1% | $59.39M-14.3% | $62.37M-9.7% | $63.36M-8.5% | $67.25M-1.7% | |
| Transfer Of Intellectual Property And Other | $81.4M+0.6% | $79.7M+3.0% | $89.11M+81.7% | $83.58M+98.7% | $80.92M-35.1% | |
| Cost of Goods Sold by Product | ||||||
| Product | $93.07M-0.6% | $93.59M+1.2% | $91.88M-3.0% | $95.16M+0.6% | $93.59M-3.5% | |
| Service | $278.98M-26.0% | $307.35M-23.6% | $323.61M-26.1% | $352.06M-19.2% | $376.75M-14.7% | |
| Revenue by Geography | ||||||
| CL | $62.71M-3.1% | $62.38M-4.1% | $60.88M-6.5% | $63.09M-3.7% | $64.69M-4.6% | |
| ES | $28.33M+11.5% | $26.72M+8.5% | $26.31M+5.6% | $26.27M+14.3% | $25.41M+10.2% | |
| IE | $55.6M+24.5% | $51.4M+6.2% | $47.12M-7.2% | $46.55M-2.9% | $44.65M-66.9% | |
| IL | $450K-73.3% | $523K-70.5% | $1.33M+15.7% | $1.38M-66.3% | $1.69M-68.2% | |
| MX | $26.23M+14.0% | $25.52M+6.9% | $24.51M+14.6% | $23.4M+8.1% | $23.01M+7.2% | |
| Other Countries | $4.43M+27.2% | $4.27M+36.8% | $4.04M+45.7% | $3.7M+43.4% | $3.49M+51.5% | |
| US | $403.36M-23.4% | $436.06M-20.2% | $477.89M-12.4% | $499.63M-9.4% | $526.47M-3.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Opko Health break its business down?
- Opko Health (OPK) reports gross profit by business across 2 parts — Diagnostics and Pharmaceutical. Each is extracted from the segment footnotes and tracked over time.
- Where does Opko Health's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Opko Health's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
